Loading organizations...
Based in Buenos Aires, Argentina, Gisens Biotech is a medical technology startup that develops portable biochip devices for real-time health monitoring and biomarker detection from patient saliva samples. The company utilizes advanced graphene-based biochips within its proprietary G-LoC device to analyze biological samples directly at the point of care, eliminating the need for complex logistics or traditional laboratory infrastructure. This diagnostic hardware provides test results in a matter of minutes with an accuracy rate exceeding 95.5 percent, enabling rapid, data-driven clinical decisions for both patients and healthcare providers. Operating as a seed-stage enterprise focused on accessible healthcare diagnostics, the firm has raised $340,000 in total equity funding to date and recently participated in the Techstars Physical Health Fort Worth accelerator program. Gisens Biotech was founded in 2019 by Luis Pierpauli, Jose Piccinini, and Waldemar Marmissolle.
Gisens Biotech has raised $420K across 1 funding round.
Gisens Biotech has raised $420K in total across 1 funding round.
Gisens Biotech has raised $420K across 1 funding round. Most recently, it raised $420K Seed in March 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2023 | $420K Seed | — | Alumni Ventures, Berkeley SkyDeck Fund, BootstrapLabs, Xuhui Shao, GRID EXPONENTIAL, R42 Group, Seven Seven SIX, SOSV | Announced |
Gisens Biotech is a Berkeley, California-based biotechnology company developing next-generation, graphene-based biosensors for point-of-care diagnostics, targeting patients with chronic diseases like kidney disease.[1][2][3] Their core product, G-LoC, is a reagent-free, home-use device that analyzes samples such as saliva in minutes with over 95.5% accuracy, detecting biomarkers without labs or logistics to enable faster clinical decisions.[2][3] It serves patients and doctors managing chronic conditions, solving the problem of slow, inaccessible testing by delivering ultrasensitive, low-cost results from a single drop—10-fold more sensitive than lateral flow assays with 99.8% predictive value and 100% sensitivity.[1][2] The company has raised funding from accelerators like Techstars Physical Health and Berkeley SkyDeck, showing early validation and growth momentum through pilots like Roche-funded kidney disease monitoring.[1][2]
Founded in 2018 (with some sources noting 2019), Gisens Biotech emerged from the labs of UC Berkeley, where co-founders Luis Pierpauli (CEO, MD from University of Buenos Aires, entrepreneur), Esteban Piccinini (CTO), and Omar Azzaroni developed a novel, industrial-scale method for producing low-cost graphene biosensors.[1][5] The idea stemmed from harnessing graphene nanotechnology—coupled with biorecognition elements like enzymes and antibodies—to create label-free sensors for ultrasensitive biomarker detection outside clinical settings.[1] Early traction included Techstars acceleration, Berkeley SkyDeck investment, and real-world validation of a COVID-19 biosensor, paving the way for chronic disease applications like at-home kidney monitoring.[1][2]
Gisens Biotech rides the wave of decentralized healthcare and point-of-care diagnostics, accelerated by COVID-19's demand for rapid, at-home testing amid rising chronic disease burdens like kidney failure.[2] Timing aligns with nanotechnology maturation—graphene's commercialization enables ultrasensitive, affordable biosensors just as aging populations and telemedicine boom strain traditional labs.[1][3] Market forces favoring them include regulatory pushes for home diagnostics, falling sensor costs, and investor interest in biotech hardware (e.g., Techstars, SkyDeck backing).[1] They influence the ecosystem by pioneering graphene in consumer health, potentially disrupting $100B+ diagnostics markets and enabling AI-driven personalized medicine through real-time biomarker data.[2][3]
Gisens Biotech is poised to scale G-LoC beyond kidney disease into multi-biomarker panels for diabetes, cardiovascular, and oncology monitoring, leveraging Roche pilots and accelerator networks for partnerships and FDA pathways.[2] Trends like AI biomarker analysis, wearable integration, and global chronic care shortages will propel them, with graphene's edge ensuring cost leadership in a crowded POC field. Their influence could evolve from niche innovator to platform provider, empowering proactive healthcare and redefining chronic disease management from reactive to predictive. This positions them as a key player in nanotechnology's biotech revolution, fulfilling their mission to bring lab-grade diagnostics home.[1][3]
Gisens Biotech has raised $420K in total across 1 funding round.
Gisens Biotech's investors include Alumni Ventures, Berkeley SkyDeck Fund, BootstrapLabs, Xuhui Shao, GRID EXPONENTIAL, R42 Group, Seven Seven Six, SOSV.
